US 12,285,440 B2
APOE4 impairs myelination via altered cholesterol biosynthesis and transport in oligodendroglia
Joel Blanchard, Arlington, MA (US); Manolis Kellis, Boston, MA (US); Li-Huei Tsai, Cambridge, MA (US); Jose Davila Velderrain, Saltillo (MX); Leyla Akay, Cambridge, MA (US); Djuna Von Maydell, Somerville, MA (US); Audrey Effenberger, Cambridge, MA (US); and Matheus Victor, Cambridge, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Mar. 14, 2022, as Appl. No. 17/694,630.
Claims priority of provisional application 63/160,877, filed on Mar. 14, 2021.
Prior Publication US 2022/0288104 A1, Sep. 15, 2022
Int. Cl. A61K 31/724 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/724 (2013.01) [A61P 25/28 (2018.01)] 15 Claims
 
1. A method of reversing an APOE4-associated cholesterol phenotype in a subject comprising administering to the subject a cyclodextrin or pharmaceutically acceptable salt thereof in an effective amount to inhibit amyloid synthesis in the subject, wherein the subject is identified as being APOE4 positive.